Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Onco-InnovationsFRA:W1H -0.73%19 PB Ratio is 85.25 as of Aug. 27, 2026, which is 2% above its 10-year median of 83.54. GuruFocus rates FRA:W1H with a GF Score™ of 19/100. The stock has 2 warning signs investors should review. Among 1,212 Biotechnology companies, Onco-Innovations ranks worse than 98.43% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-08-27), Onco-Innovations's share price is €0.341. Onco-Innovations's Book Value per Share for the quarter that ended in Apr. 2026 was €0.00. Hence, Onco-Innovations's PB Ratio of today is 85.25.
The historical rank and industry rank for Onco-Innovations's PB Ratio or its related term are showing as below:
FRA:W1H'
s PB Ratio Range Over the Past 10 Years
Min: 32.5 Med: 83.54 Max: 202.86
Current: 80
During the past 4 years, Onco-Innovations's highest PB Ratio was 202.86. The lowest was 32.50. And the median was 83.54.
FRA:W1H's PB Ratio is ranked worse than 98.43% of 1212
companies
in the Biotechnology industry
Industry Median: 2.95
vs FRA:W1H: 80.00
During the past 12 months, Onco-Innovations's average Book Value Per Share Growth Rate was -80.60% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Onco-Innovations PB Ratio Related Terms
Onco-Innovations PB Ratio Historical Data
* Premium members only.
The historical data trend for Onco-Innovations's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Onco-Innovations's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Onco-Innovations PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Onco-Innovations's PB Ratio distribution charts can be found below:
* The bar in red indicates where Onco-Innovations's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Onco-Innovations (FRA:W1H) has a PB Ratio of 85.25 as of Aug. 27, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Onco-Innovations and its competitors. This is near median its historical median of 83.54. Over the past decade, Onco-Innovations' PB Ratio has ranged from 32.50 to 202.86. According to the industry distribution chart, Onco-Innovations ranks #1193 out of 1212 companies in the Biotechnology industry, placing it in the top 98.4%.
Is Onco-Innovations' PB Ratio too high?
Onco-Innovations' current PB Ratio of 85.25 is near median its 10-year median of 83.54. Over the past 10 years, this metric has ranged from a low of 32.50 to a high of 202.86. The Biotechnology industry median PB Ratio is 2.95. Onco-Innovations' value of 85.25 is 2789.8% above this industry median. Based on the distribution chart, Onco-Innovations ranks #1193 out of 1212 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Onco-Innovations has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Onco-Innovations' PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Onco-Innovations ranks #1193 out of 1212 companies for PB Ratio. This places Onco-Innovations in the lower half of its industry. The industry median PB Ratio is 2.95. Onco-Innovations' value of 85.25 is 2789.8% above this benchmark. Historically, Onco-Innovations' own PB Ratio has ranged from 32.50 to 202.86 over the past decade. While the company's 10-year median is 83.54 vs. the industry median of 2.95, Onco-Innovations has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.95, based on 1,212 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Onco-Innovations's current PB Ratio of 85.25 is 2789.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Onco-Innovations and its competitors. For the Biotechnology industry, the median PB Ratio is 2.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Onco-Innovations's current PB Ratio is 85.25, which is near median its own 10-year median of 83.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Onco-Innovations stock overvalued right now?
Onco-Innovations (FRA:W1H) has a current PB Ratio of 85.25. The current PB Ratio is 85.25, which is near median its 10-year median of 83.54 and 2789.8% above the Biotechnology industry median of 2.95. Onco-Innovations' overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Onco-Innovations (FRA:W1H), the current PB Ratio is 85.25 as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Onco-Innovations Ltd is a pre-clinical stage biotechnology company working on developing drug candidates that can increase the effectiveness of current cancer treatments.
19GF Score
Get the complete analysis for FRA:W1H
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:W1H has been successfully added to your 
